Mesut Remzi
Overview
Explore the profile of Mesut Remzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
3462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yurdakul O, Seitz C, Tuncel A, Veser J, Hassler M, Shariat S, et al.
Urol Int
. 2025 Jan;
:1-8.
PMID: 39884258
Introduction: This research investigates the influence of the medical personnel shortage on the treatment of urolithiasis by comparing the complication rates in patients with urinary stones who undergo ureterorenoscopy with...
2.
Yurdakul O, Tuncel A, Hassler M, Oberneder K, Gamez D, Remzi M
Wien Klin Wochenschr
. 2024 Oct;
PMID: 39466416
Introduction: Socioeconomic disparities have been linked to delayed prostate cancer diagnosis and poorer outcomes in various countries. This study aims to evaluate the socioeconomic disparities in prostate cancer diagnostics in...
3.
Tsuboi I, Rajwa P, Campi R, Miszczyk M, Fazekas T, Matsukawa A, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39455341
Background And Objective: While active surveillance (AS) is an alternative to surgical interventions in patients with small renal masses (SRMs), evidence regarding its oncological efficacy is still debated. We aimed...
4.
Tsuboi I, Kardoust Parizi M, Matsukawa A, Mancon S, Miszczyk M, Schulz R, et al.
Urol Oncol
. 2024 Oct;
PMID: 39379210
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a high recurrence rate after surgical therapy with curative intent. Adjuvant radiotherapy (RT) and mitotane therapy have been proposed as...
5.
Bronimann S, Garstka N, Remzi M
Curr Opin Urol
. 2022 Nov;
33(1):50-58.
PMID: 36444650
Purpose Of Review: Adrenocortical carcinoma (ACC) is a rare, aggressive disease with a paucity of data and great variability between published studies regarding its treatment. This review provides information on...
6.
Vartolomei M, Remzi M, Fajkovic H, Shariat S
J Clin Med
. 2022 Oct;
11(20).
PMID: 36294486
Robot-assisted partial nephrectomy (RAPN) is used more and more in present days as a therapy option for surgical treatment of cT1 renal masses. Current guidelines equally recommend open (OPN), laparoscopic...
7.
Garstka N, Remzi M
Curr Opin Urol
. 2022 Oct;
33(1):59-63.
PMID: 36239402
Purpose Of Review: Adrenal lesions are commonly discovered on abdominal imaging studies, whereas some patients with adrenal tumors present with symptoms of homonal excess. They are categorized as either hormone...
8.
Alimohammadi A, Fajkovic H, Remzi M, Shariat S, Schmidinger M
Expert Rev Clin Pharmacol
. 2022 Mar;
15(2):187-195.
PMID: 35285369
Introduction: Therapies combining either two immune check-point inhibitors (ICIs) or an ICI and a tyrosine kinase inhibitor (TKI) have been shown to improve overall survival (OS), progression-free survival (PFS) and...
9.
Stangl-Kremser J, Muto G, Grosso A, Briganti A, Comperat E, Di Maida F, et al.
Urol Oncol
. 2022 Mar;
40(6):243-261.
PMID: 35241364
Patients with upper tract urothelial carcinoma (UTUC) often have a delayed diagnosis and by then, present with advanced disease which has been shown to be associated with lymphovascular invasion (LVI)....
10.
Quhal F, Mori K, Fajkovic H, Remzi M, Shariat S, Schmidinger M
Curr Opin Urol
. 2021 Nov;
32(1):61-68.
PMID: 34720102
Purpose Of Review: To perform indirect comparisons of efficacy and safety of first-line immune checkpoint inhibitor (ICI)-based combination therapies for renal cell carcinoma with sarcomatoid features (sRCC). Recent Findings: Five...